HemoGenix® is the only company in the world that has developed, validated and patented in vitro assays specifically to detect and predict hemotoxicity for virtually any agent.
Our proprietary Hemotoxicology Predictive Paradigm was developed during the validation of the HALO® Platform. The latter was validated against the Registry of Cytotoxicity Prediction Model and means that the HALO® Platform is a validated cytotoxicity assay.
In addition, the results obtained from HALO® allow it to be used not only to predict the response of the lympho-hematopoietic system to different agents, but also can be used to predict starting doses for pre-clinical animal studies and even dosing for human clinical trials.
With the introduction of the HALO®-96 SEC and HALO®-384 HT platforms, all the decision-making tools are now available to perform rapid, predictive and reliable hemotoxicity testing so that compounds can be ranked at any stage during the drug discovery AND development pipeline, from primary and/or secondary screening and ADME/Tox to pre-clinical development and even patient monitoring during clinical trials.
This unique and powerful capability can only be obtained from HemoGenix®.
The following pages describe the background and our hemotoxicity assays. Please contact us to discuss how we can help you achieve your goals.